[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"King's College Hospital NHS Trust\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":622},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,34,0,25,[9,46,76,97,126,147,175,198,222,246,276,301,322,346,368,390,420,447,468,489,516,537,556,579,599],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100639188","biodegradable-stents-in-primary-sclerosing-cholangitis-100639188",false,"NCT07607353","Biodegradable Stents in Primary Sclerosing Cholangitis","Pilot Study of Biodegradable STents in Primary Sclerosing Cholangitis - BSTPSC","BSTPSC","Inclusion Criteria:\n\n* PSC patients with a high grade stricture\n\nExclusion Criteria:\n\n* Prior stenting or balloon dilatation within the previous 4 months\n* Signs of bacterial cholangitis as defined by definite cholangitis\n* Change of UDCA therapy within 4 weeks\n* Inability to give informed consent\n* Biliary cirrhosis with Child Pugh score \\> 8\n* Estimated transplant free survival \\\u003C 2 years as calculated by Mayo score \\> 2\n* Suspicion of cholangiocarcinoma, reflected by an imaging study suggestive of metastasis, MRCP with mass lesion with contrast enhancenment, or rise in CA19.9 of \\> 63 U\u002Fml in the previous 4 months together with an absolute value \\> 130 U\u002Fml\n* Signs of current malignancy other than basal cell carcinoma\n* Life expectancy \\\u003C 24 months\n* Women pregnant at the time of screening\n* HIV or acute or chronic hepatitis B or hepatitis C or substance (drug or alcohol) misure within the previous 2 years.","ALL","18 Years",{"count":21,"type":22},20,"ESTIMATED","INTERVENTIONAL",[25],"NA","In patients with PSC, endoscopic therapy of strictures aims to improve cholestasis by relieving the biliary obstruction via endoscopic biliary dilatation with consideration of plastic stents in strictures refractory to dilatation due to the risk of pancreatitis and cholangitis . Short term stents have been shown to have similar recurrence-free rates compared to dilatation in a randomised control trial; however, this was terminated after interim analysis due to higher rates of serious adverse events in the stent group. The long term benefits are unclear; however, it may lead to improved survival compared to predicted survival. In this group of patients with limited treatment options, biodegradable stents may provide an attractive additional treatment modality in the management of high grade strictures.",[28],"Primary Sclerosing Cholangitis (PSC)",[30,31,32],"PSC","ERCP","Biodegradable stents","RECRUITING","2026-05-27",{"date":36,"type":37},"2026-05-29","ACTUAL",{"date":39,"type":37},"2026-03-01",{"date":41,"type":22},"2027-04-01",{"name":43,"class":44},"King's College Hospital NHS Trust","OTHER",1,{"id":47,"slug":48,"hasResults":12,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":12,"sex":18,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":23,"phases":57,"briefSummary":58,"conditions":59,"keywords":63,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":45},"100639553","automated-oxygen-control-in-preterms-on-non-invasive-ventilation-100639553","NCT07622563","Automated Oxygen Control in Preterms on Non-invasive Ventilation","Randomised Controlled Trial of Closed-loop Automated Oxygen Control in Preterm Infants Receiving Non-invasive Respiratory Support","Inclusion Criteria:\n\nPreterm infants \\\u003C34 weeks of gestation and at any postnatal age on non-invasive respiratory support including:\n\n* non-invasive positive pressure ventilation (NIPPV)\n* nasal CPAP\n* HHFNC oxygen, either as primary or post extubation respiratory support.\n\nExclusion Criteria:\n\n* Infants with congenital cyanotic heart disease.\n* Infants with other know major congenital abnormalities.","22 Weeks","34 Weeks",{"count":56,"type":22},76,[25],"This randomised controlled trial aims to investigate the effectiveness of closed-loop automated oxygen control (CLAC) in preterm infants receiving non-invasive respiratory support and determine if it reduces the duration of supplementary oxygen treatment and improves achievement of oxygen saturation targets, reduces the incidences of hypoxia and hyperoxia, the number of manual adjustments to the inspired oxygen concentration (FiO2), and adverse outcomes including bronchopulmonary dysplasia (BPD).\n\nThe study will take place at King's College Hospital neonatal intensive care unit (NICU). Parents of preterm infants born at less than 34 weeks of gestation and receiving non-invasive respiratory support will be approached, informed and if appropriate consented to join the trial.\n\nParticipants will be randomised to receiving either automated or manual oxygen control.\n\nThe study will measure outcomes including the duration of supplementary oxygen treatment, the percentage of time spent within oxygen saturation targets, the incidences of hypoxia and hyperoxia, the number of manual FiO2 adjustments required, the overall duration of non-invasive respiratory support and length of neonatal unit stay, and the incidence of BPD at 36 weeks postmenstrual age (PMA). Results will be compared between the two groups.",[60,61,62],"Infant","Premature","Airway Morbidity",[64,65,66,67],"automated oxygen control","non-invasive respiratory support","randomised controled trial","neonates","NOT_YET_RECRUITING",{"date":70,"type":37},"2026-06-03",{"date":72,"type":22},"2026-06-01",{"date":74,"type":22},"2027-09",{"name":43,"class":44},{"id":77,"slug":78,"hasResults":12,"nctId":79,"briefTitle":80,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":12,"sex":83,"minAge":84,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":23,"phases":87,"briefSummary":88,"conditions":89,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":93,"completionDateStruct":94,"leadSponsor":96,"locationsCount":4},"100637170","the-psychological-effects-of-miscarriage-prediction-score-a-prospective-study-100637170","NCT07609602","The Psychological Effects of Miscarriage Prediction Score: A Prospective Study","PEMPS","Inclusion Criteria:\n\n* Have capacity to understand the study and to provide signed and dated informed consent.\n* Willing to comply with all study procedures and be available for the duration of the study including consenting to follow up of the pregnancy outcome by letter, phone or email according to individual preference.\n* Age 16 years or over\n* Single live ongoing intrauterine pregnancy less than 12 weeks gestation\n\nExclusion Criteria:\n\nWomen with pregnancies of unknown location, ectopic pregnancies or early pregnancy prior to an embryo being seen or an embryo without a heartbeat.\n\n* Multiple pregnancies\n* Those undergoing assessment or treatment for a psychological condition by a psychiatrist\n* Those who do not speak English or require a translator\n* Women who have taken part in another clinical trial in the last 3 months.","FEMALE","16 Years",{"count":86,"type":22},372,[25],"Patients Under 12 Weeks Pregnant With a Single Ongoing Pregnancy Attending the EPU Will be Randomly Assigned to Receive Their Personalised Miscarriage Risk Score or Not. The Study Explores Whether Sharing This Score Affects Anxiety and Whether Patients Find the Information Helpful and Acceptable. (PEMPS)",[90],"Early Pregnancy Bleeding","2026-05-21",{"date":34,"type":37},{"date":72,"type":22},{"date":95,"type":22},"2028-06-01",{"name":43,"class":44},{"id":98,"slug":99,"hasResults":12,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":103,"eligibilityCriteria":104,"healthyVolunteers":12,"sex":18,"minAge":105,"maxAge":106,"enrollmentInfo":107,"targetDuration":4,"studyType":23,"phases":109,"briefSummary":111,"conditions":112,"keywords":116,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":125},"100413450","phase-3-vitrectomy-subretinal-tissue-plasminogen-activator-tpa-and-intravitreal-gas-for-submacular-haemorrhage-secondary-to-exudative-wet-age-related-macular-degeneration-tiger-100413450","NCT04663750","Vitrectomy, Subretinal Tissue Plasminogen Activator (TPA) and Intravitreal Gas for Submacular Haemorrhage Secondary to Exudative (Wet) Age-related Macular Degeneration (TIGER).","Vitrectomy, Subretinal Tissue Plasminogen Activator and Intravitreal Gas for Submacular Haemorrhage Secondary to Exudative Age-Related Macular Degeneration (TIGER): a Phase 3, Pan-European, Two-group, Observer-masked, Superiority, Randomised Controlled Surgical Trial.","TIGER","Inclusion Criteria:\n\nGeneral\n\n1. Males or females aged at least 50 years\n\n   Study eye\n2. SMH, comprising sub-neuroretinal haemorrhage with or without sub-RPE haemorrhage, that occurs secondary to treatment naïve, or previously treated exudative AMD, including choroidal neovascularisation (CNV), idiopathic polypoidal choroidal vasculopathy (IPCV) and retinal angiomatous proliferation (RAP).\n3. SMH involving the foveal centre that measures at least 1 disc diameter in greatest linear dimension.\n4. Sub-neuroretinal haemorrhage at least 125 microns thick, measured at the foveal centre using spectral-domain optical coherence tomography (SD-OCT).\n5. BCVA between counting fingers and an Early Treatment of Diabetic Retinopathy Study (ETDRS) letter score of 70, inclusive.\n\nExclusion Criteria:\n\nGeneral\n\n1. Serious allergy to fluorescein or indocyanine green (ICG).\n2. Hypersensitivity to alteplase, gentamicin, arginine, phosphoric acid, polysorbate 80 or aflibercept.\n3. Stroke, transient ischaemic attack or myocardial infarction within 6 months.\n4. Participation in another interventional study within 12 weeks of enrolment or planned to occur during this study.\n5. Women who are breast feeding, pregnant, or planning to become pregnant during the clinical trial. Any sexually active women of childbearing potential must agree continued abstinence from heterosexual intercourse or to use highly effective methods of birth control for the duration up to 12 weeks after administration of IMP or the last administration of aflibercept on the trial. Men must also agree to use a condom if their partner is of child bearing potential, even if they have had a successful vasectomy. Females of childbearing potential are females who have experienced menarche and are not surgically sterilised (e.g. hysterectomy or bilateral salpingectomy) or post-menopausal (defined as at least 1 year since last regular menstrual period). Highly effective methods of birth control are those with a failure rate of \\\u003C 1% per year when employed consistently and correctly, eg. combined (oestrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation via oral, intravaginal, and transdermal routes; progestogen-only hormonal contraception associated with inhibition of ovulation via oral, injectable, implantable, intrauterine device (IUD), or intrauterine hormone-releasing system ( IUS); or vasectomised partner.\n6. International Normalised Ratio (INR) greater than 3.5, unless it is anticipated that the INR can be brought below this level prior to vitrectomy, balancing the systemic risks with those of intraocular haemorrhage\\*.\n7. Unwilling, unable, or unlikely to return for scheduled follow-up for the duration of the trial.\n8. Any other condition which, in the opinion of the investigator, would prevent the participant from granting informed consent or complying with the protocol, such as dementia, mental illness, or serious systemic medical disease.\n\n   Study eye\n9. SMH that is known or estimated to have been present for longer than 15 days, as evidenced by history, pre-trial clinical documentation, or fundus appearance.\n10. SMH due to eye disease other than exudative AMD.\n11. Current active proliferative diabetic retinopathy.\n12. Current intraocular inflammation.\n13. Current ocular or periocular infection other than blepharitis.\n14. Current or known former high myopia (\\>6 dioptres).\n15. Aphakia.\n16. Other current or pre-existing ocular conditions that, in the opinion of the Investigator, will preclude any improvement in BCVA following resolution of SMH, such as severe central macular atrophy or fibrosis, dense amblyopia, macular hole involving the fovea, or very poor BCVA prior to presentation with SMH (counting fingers or worse).\n17. Inadequate pupillary dilation or significant media opacities, which will prevent adequate clinical evaluation of the posterior segment or fundus imaging.\n18. Intraocular surgery within 12 weeks of enrolment except for uncomplicated cataract surgery, which is permitted within 8 weeks of enrolment.\n\n    * Applies only to participants receiving warfarin.","50 Years","120 Years",{"count":108,"type":22},210,[110],"PHASE3","The centre of the retina (macula) at the back of the eye contains cells that give us our central vision that we use for reading and recognising faces. These cells can be damaged by a disease called wet age-related macular degeneration (AMD), where new abnormal blood vessels grow through the macula and leak fluid. This can affect vision. In some cases, wet AMD can also cause a bleed under the macula, known as a submacular haemorrhage (SMH), which can lead to marked and persistent loss of vision in the eye.\n\nThe current standard treatment for wet AMD is to give injections containing 'anti-VEGF' drugs into the eye. Anti-VEGF drugs reduce the leakage of fluid so that the macula can become dry again and sight can improve.\n\nAnti-VEGFs are also the current standard of care for SMH, mainly because there is no licensed treatment for the SMH itself (patients with SMH were excluded from most wet AMD studies).\n\nThe purpose of this study therefore is to compare two treatments:\n\n1. Standard treatment for wet AMD (anti-VEGF injections).\n2. Standard treatment above plus surgery. This study will find out if having surgery alongside anti-VEGF injections can improve vision further over the current standard treatment of anti-VEGF injections alone.",[113,114,115],"Eye Diseases","Macular Degeneration, Wet","Sub-Macular Hemorrhage",[114,115],"2026-05-13",{"date":119,"type":37},"2026-05-15",{"date":121,"type":37},"2021-04-16",{"date":123,"type":22},"2028-12",{"name":43,"class":44},36,{"id":127,"slug":128,"hasResults":12,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":132,"eligibilityCriteria":133,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":134,"targetDuration":4,"studyType":23,"phases":136,"briefSummary":137,"conditions":138,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":146,"locationsCount":4},"100635857","the-arise-trial-compares-whether-giving-routine-steroid-replacement-or-using-targeted-blood-tests-to-guide-replacement-better-protects-certain-patients-from-adrenal-insufficiency-after-the-removal-of-a-diseased-adrenal-gland-100635857","NCT07558135","The ARISE Trial Compares Whether Giving Routine Steroid Replacement or Using Targeted Blood Tests to Guide Replacement Better Protects Certain Patients From Adrenal Insufficiency After the Removal of a Diseased Adrenal Gland.","Adrenalectomy Recovery and Sustained Insufficiency After Steroid Exposure (ARISE): A Randomised Controlled Trial","ARISE","Inclusion Criteria:\n\n* Recommended for adrenalectomy following adrenal multidisciplinary discussion\n* ≥18 years old\n* Ability to consent\n\nExclusion Criteria:\n\n* Overt Cushing's syndrome\n* Pregnancy\n* Pre-existing confirmed adrenal insufficiency\n* Pre-existing steroid therapy (including high dose steroid inhalers)\n* History of adrenalectomy\n* Bilateral disease as assessed radiologically and clinically",{"count":135,"type":22},96,[25],"Adrenalectomy is an operation to remove one of the adrenal glands. It is commonly performed to treat adrenal tumours or conditions that cause excess hormone production. The adrenal glands produce important hormones, including cortisol and aldosterone, which help regulate blood pressure, metabolism and the body's response to stress.\n\nAfter adrenalectomy, some patients may develop adrenal insufficiency, a condition in which the body does not produce enough of these essential hormones. In severe cases, this can lead to an Addisonian (adrenal) crisis, a life-threatening emergency that can cause shock, organ failure and death if not treated promptly.\n\nThe risk of adrenal insufficiency after surgery depends largely on cortisol levels before the operation. In patients with Cushing's syndrome, where there is excessive cortisol production, the risk of adrenal insufficiency after adrenalectomy is almost 100%. For this reason, these patients routinely receive steroid replacement treatment after surgery to replace missing hormones and prevent adrenal crisis.\n\nFor other patients undergoing adrenalectomy, the best management approach is less clear. Patients with mild autonomous cortisol secretion (MACS) have a moderate risk of adrenal insufficiency - around 50-65%. Patients with normal cortisol secretion (NCS) may also develop adrenal insufficiency because one adrenal gland has been removed, occurring in around 20-37% of cases.\n\nInternational medical guidelines currently disagree on how best to manage these patients after surgery. Some recommend measuring cortisol levels the morning after surgery and treating only if levels are low, while others recommend giving steroid treatment to all patients with mild cortisol excess. There is currently no clear guidance for patients with normal cortisol secretion.\n\nThis study will compare these management strategies to determine which approach best reduces the risk of adrenal insufficiency after adrenalectomy. The study will be conducted at King's College Hospital and will run for approximately two years.",[139],"Adrenal Gland Disease","2026-04-23",{"date":142,"type":37},"2026-04-30",{"date":144,"type":22},"2026-09",{"date":123,"type":22},{"name":43,"class":44},{"id":148,"slug":149,"hasResults":12,"nctId":150,"briefTitle":151,"officialTitle":152,"acronym":4,"eligibilityCriteria":153,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":154,"targetDuration":4,"studyType":23,"phases":156,"briefSummary":157,"conditions":158,"keywords":161,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":174,"locationsCount":45},"100633907","feasibility-of-good-boost-for-adults-awaiting-total-knee-replacement-100633907","NCT07532785","Feasibility of Good Boost+ for Adults Awaiting Total Knee Replacement","Feasibility of a Community-Based Aquatic Exercise and Peer Support Intervention (Good Boost+) for Adults on Knee Replacement Waiting Lists: A Randomised Hybrid Type 1 Effectiveness-Implementation Feasibility Trial","Inclusion Criteria:\n\nAged 18 years or over. Registered on a wait list for primary total knee replacement with sufficient time to complete the 6 week intervention and follow up assessments prior to surgery.\n\nModerate self reported intensity knee joint pain within the previous month, defined as ≥4 but \\\u003C10 on the 11 point Numeric Pain Rating Scale (NPRS: 0 = no pain, 10 = worst pain imaginable).\n\nWilling and able to participate in a six week programme of weekly group water-based exercise at specified leisure centre swimming pools in Southwark and three times weekly land-based exercise training in a private setting.\n\nWilling to pay £4.30 for water-based exercise sessions 5 \\& 6. This fee is in line with the usual cost of over 60s group exercise classes at local leisure centres.\n\nAccess to a smart phone or tablet computer with internet access. Willing and able to accept either trial arm allocation. Willing and able to give informed consent.\n\nExclusion Criteria:\n\nIndividuals scheduled to have another major joint replacement (e.g. contralateral knee, hip or shoulder) within the study period.\n\nIndividuals on the waiting list for revision surgery of a previous knee replacement.\n\nIndividuals with active inflammatory arthritis (e.g., RA, PsA, lupus, axial SpA) that is clinically symptomatic or requires ongoing immunosuppressive therapy to control disease activity.\n\nIndividuals who self-report being advised by a healthcare professional not to exercise.\n\nIndividuals who have previously participated in water-based exercise sessions delivered via the Good Boost HUB application.\n\nParticipating or planning to participate in another interventional clinical study\u002Ftrial during the study period that in the opinion of the investigator could affect the outcomes of this study.\n\nIndividuals unable to understand written or spoken English or communicate sufficiently well in English to participate despite assistance from a family member or friend.\n\nIndividuals unable to comply with the protocol \u002F requirements of study participation.\n\nIndividuals with any other severe concomitant disease that, in the opinion of the investigator might interfere with trial procedures and\u002For assessments.",{"count":155,"type":22},48,[25],"The goal of this randomised controlled feasibility trial is to find out whether it is possible to run a larger study of the Good Boost+ community based rehabilitation programme for people waiting for a primary total knee replacement.\n\nThe study will look at how many people are willing to take part, whether they stay in the study, and whether they can follow the Good Boost+ programme as planned. It will also explore how acceptable the programme is to patients, NHS staff and leisure centre staff, and which outcome measures are most useful for a future full scale trial. The study will also look at what helps or hinders delivery of the programme in real world NHS and community settings.\n\nThe main questions it aims to answer are:\n\n* How many people waiting for knee replacement surgery are willing to take part in the study\n* Whether participants can continue with the Good Boost+ programme as planned over the study period\n* Which outcome measures best capture any potential benefits of the programme\n* How acceptable the programme is to patients, NHS and leisure centre staff\n* What helps or makes it difficult to deliver the programme in practice.\n\nParticipants will be randomly assigned to one of two groups.\n\n* Usual NHS care or\n* Usual NHS care plus the Good Boost+ programme\n\nParticipants in the Good Boost+ programme will take part in six weekly group water based exercise sessions held in local swimming pools, as well as land based exercise sessions that can be done individually or by joining a virtual group. The exercise sessions are delivered through Good Boost's digital technology, using small waterproof tablet computers at swimming pools, and smartphones or computers for land-based sessions. Physiotherapy staff will provide guidance throughout, and volunteers will offer refreshments after pool sessions to support social connection.\n\nAll participants, including those receiving usual NHS care only, will be asked to complete an exercise diary, rate their knee pain each week, and complete short questionnaires at 6 and 10 weeks after joining the study.",[159,160],"Osteoarthritis (Knee)","Arthroplasties, Knee Replacement",[162,163,164,165,166],"Total Knee Replacement","Prehabilitation","Feasibility","Randomised controlled trial","Implementation","2026-04-09",{"date":169,"type":37},"2026-04-16",{"date":171,"type":22},"2026-06",{"date":173,"type":22},"2028-02",{"name":43,"class":44},{"id":176,"slug":177,"hasResults":12,"nctId":178,"briefTitle":179,"officialTitle":179,"acronym":180,"eligibilityCriteria":181,"healthyVolunteers":182,"sex":18,"minAge":183,"maxAge":4,"enrollmentInfo":184,"targetDuration":4,"studyType":186,"phases":4,"briefSummary":187,"conditions":188,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":191,"startDateStruct":193,"completionDateStruct":195,"leadSponsor":197,"locationsCount":45},"100560059","dynamic-renal-assessment-novel-methods-to-assess-kidney-functional-reserve-100560059","NCT06572215","DYNAMic Renal Assessment: NOvel Methods to Assess KIDNEY Functional Reserve","DYNAMO","Inclusion:\n\n* Patients with sickle cell nephropathy, diagnosed clinically or histologically. Sickle Cell patients will be confirmed Hb SS and eGFR (CKD-EPI) ≥ 135 ml\u002Fmin\u002F1.73m2 OR\n* Previous living kidney donation\n* Age ≥ 4No contraindication or known allergy to any trial medications.\n* Willing and able to provide written informed consent\n\nExclusion:\n\n* Aged \\< 40\n* Unable or unwilling to provide informed consent\n* Breastfeeding or pregnant women\n* Patients involved in other interventional research studies.",true,"40 Years",{"count":185,"type":22},44,"OBSERVATIONAL","This is a feasibility study to assess new, more practical ways of measuring renal reserve.",[189],"Chronic Kidney Diseases","2026-03-26",{"date":192,"type":37},"2026-04-01",{"date":194,"type":37},"2023-12-14",{"date":196,"type":22},"2027-12-31",{"name":43,"class":44},{"id":199,"slug":200,"hasResults":12,"nctId":201,"briefTitle":202,"officialTitle":203,"acronym":204,"eligibilityCriteria":205,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":206,"targetDuration":4,"studyType":186,"phases":4,"briefSummary":208,"conditions":209,"keywords":211,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":215,"lastUpdatePostDateStruct":216,"startDateStruct":218,"completionDateStruct":220,"leadSponsor":221,"locationsCount":45},"100540506","pulsed-field-ablation-of-colorectal-polyps-100540506","NCT06317727","PULSed Field ablAtion of coloRectal Polyps","Pulsed Field Ablation of Colorectal Polyps","PULSAR","Inclusion Criteria:\n\n* \\> 18 years of age.\n* Ability to review the consent form prior to enrolment into the study • Patients must be mentally capable of understanding the information given • Patients must give written informed consent prior to undergoing any study-specific procedures.\n* Patients must have at least one polyp (treatment naive, recurrent or residual) measuring \\>5mm, located distal to the splenic flexure(i.e descending colon, Sigmoid colon, recto sigmoid junction and the rectum above the dentate line)\n* Polyp(s) must be classified as Type 1 or Type 2, based on NICE (Narrow Band Imaging International Colorectal Endoscopic) classification; OR Type 1 or Type 2A \u002F2B based on JNET (Japan Narrow Band Imaging Expert Team) classification\n* Patients must have a World Health Organization (WHO) performance status ≤ 2 . Patients must have a life expectancy of at least 6 months\n\nExclusion Criteria:\n\n* \\\u003C 18 years of age.\n* Patients who are incapacitated, unconscious or from a vulnerable population. • Patient who is pregnant or breastfeeding\n* Patients unable to provide their own informed consent\n* Patients with complex \u002F challenging polyp(s), including but not limited to those that are: o \\>20mm in size o Flat\u002Fbulky in shape o Extending beyond 2 haustra folds or occupying more than 1\u002F3rd of the lumenal circumference o Located on the right colon proximal to the splenic flexure, ileocecal valve, hepatic and splenic flexure or dentate line of the rectum o Fibrosis from large lateral spreading lesions\n* Patients with NICE Type 3 category polyps, OR JNET Type 3 polyps OR Kudo Vi pit pattern polyps\n* Patients with British Society of Gastroenterology (BSG) category C (high risk polyps).\n* Five or more polyps in a single patient\n* Grossly inflamed colonic mucosa with bleeding or ulcers\n* Implanted colonic stents\n* Polyposis syndromes",{"count":207,"type":22},30,"The goal of this observational study is to learn about the role of electroporation (the use of small electric pulses applied to tissue) in the treatment (ablation) of colorectal polyps. The main questions to answer in this pilot phase of the study are:\n\n1. The safety of pulsed field ablation (PFA) for the removal of colorectal polyps\n2. The efficacy and feasibility of PFA in the treatment of colorectal polyps using metrics such as treatment coverage, treatment time, post treatment fibrosis, post treatment recurrence and patient satisfaction",[210],"Colon Polyp",[212,213,214],"Colorectal polyps","Irreversible electroporation","Endoscopic ablation","2026-02-27",{"date":217,"type":37},"2026-03-03",{"date":219,"type":37},"2025-03-26",{"date":173,"type":22},{"name":43,"class":44},{"id":223,"slug":224,"hasResults":12,"nctId":225,"briefTitle":226,"officialTitle":226,"acronym":227,"eligibilityCriteria":228,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":229,"enrollmentInfo":230,"targetDuration":4,"studyType":23,"phases":232,"briefSummary":233,"conditions":234,"keywords":237,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":239,"lastUpdatePostDateStruct":240,"startDateStruct":242,"completionDateStruct":243,"leadSponsor":245,"locationsCount":45},"100622535","surgery-and-laser-interstitial-thermal-therapy-for-bilateral-glioblastomas-100622535","NCT07384884","Surgery and Laser Interstitial Thermal Therapy for Bilateral Glioblastomas","SLITT-GBM","Inclusion Criteria:\n\n1. Presumptive diagnosis of bGBM as per preoperative MRI and MDT assessment\n2. Presumed residual \u002F smaller component of the bGBM has to be \\\u003C 2.5cm\n3. Performance Status 0-1\n4. Able to consent for the study\n\nExclusion Criteria:\n\n1. bGBM measuring \\>2.5 cm in both hemispheres.\n2. Tumour progression between surgical debulking and LITT treatment\n3. Severe complications after surgery (hydrocephalus, infection, heamatoma, stroke)","80 Years",{"count":231,"type":22},12,[25],"Butterfly glioblastomas (bGBM), defined as tumours crossing the midline to involve hemispheres bilaterally, have a dismal prognosis with a median survival of 3.3-6 months and only 9% of patients with bGBM survive 2-years. These figures put bGBM in the worst end of the spectrum of GBM prognosis, significantly inferior to the survival figures quoted in the literature with standard of care - 14.6 months - particularly when 5-aminolevulinic acid is used as surgical adjuvant - 17.47 months.\n\nDespite the poor outcome of this disease, there is preliminary evidence suggesting that active oncology treatment can impact the survival of patients with this condition.With particular regards to surgical resection versus biopsy, there is a suggestion that resection improves overall survival at 6 months with no clear difference at 12 and 18 months of follow up.\n\nLaser-induced thermal therapy (LITT) is a minimally invasive laser ablation technique used in a range of brain tumours, including glioblastomas, with similar overall survival to the ones reported for open surgery in patients with lesions not amenable to open resection. The minimally invasive nature of this technique, significantly reducing the collateral damage to the surrounding brain structures, suggests Its potential in the treatment of this bGBM \\[14\\] with significant implications as a deficit-sparing technique, particularly if associated with preoperative and intraoperative monitoring and mapping techniques.\n\nThe SLITT-GBM study will combine unilateral open surgery for maximal tumour resection with contralateral LITT to the smaller component\u002Fresidual.",[235,236],"Brain Tumours","GBM",[238],"brain tumour","2026-02-17",{"date":241,"type":37},"2026-02-19",{"date":39,"type":22},{"date":244,"type":22},"2027-07-01",{"name":43,"class":44},{"id":247,"slug":248,"hasResults":12,"nctId":249,"briefTitle":250,"officialTitle":251,"acronym":4,"eligibilityCriteria":252,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":253,"targetDuration":4,"studyType":186,"phases":4,"briefSummary":255,"conditions":256,"keywords":261,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":267,"lastUpdatePostDateStruct":268,"startDateStruct":270,"completionDateStruct":272,"leadSponsor":274,"locationsCount":275},"100624979","death-dying-violence-and-aggression-as-shown-on-medical-television-series-100624979","NCT07416669","Death, Dying, Violence and Aggression as Shown on Medical Television Series.","End of Life, Violence and Aggression on TV.","Inclusion Criteria:\n\n* Any are clearly visible and\u002For audible, intentional acts of violence occurring as self-contained scenes within an episode, set in a hospital environment, and taking place between two or more individuals in a medical or professional treatment setting.\n* All patients dying within the hospital setting. The death scene must be explicitly shown or named (e.g., flatline, burial, covering of the body). The death must be visibly depicted on screen (the viewer must see the death happen).\n\nExclusion Criteria:\n\n* Violence: Violence outside the hospital. Self-harming behaviour or acts of violence that originate from a purely private context and do not arise within a professional medical setting.\n* Death: Death outside the hospital. Stories or mentions of death without visual depiction do not count. Implied or off-screen deaths without explicit confirmation or depiction are excluded. Implied or off-screen deaths without explicit confirmation or depiction are excluded.",{"count":254,"type":22},500,"Medical TV dramas have become very popular in recent years. These shows are mainly created for entertainment and often do not reflect what really happens in hospitals. However, television plays an important role in sharing information, shaping how people think, and teaching the public about medicine.\n\nDeath and dying in hospitals, especially in Intensive Care Units (ICUs), are highly emotional experiences. In real life, these situations often turn out very differently from what patients and families expect. Because of this, it is important to understand how medical TV shows portray major hospital events such as end-of-life care, death, and the delivery of bad news. When what is shown on TV does not match the reality of ICU care, it can lead to unrealistic expectations, false hope, and greater distress for patients and their families at the end of life.\n\nAt the same time, violence and aggression towards healthcare providers have increased in recent years. This can include verbal abuse as well as physical attacks. Looking at how healthcare workers are treated in medical TV shows may help us understand whether these programmes influence what behaviour is seen as acceptable. Since violence against healthcare staff has become especially concerning since the COVID-19 pandemic, the possible role of media should not be ignored, even though many factors are involved.\n\nThis study aims to describe how death and dying are shown in popular medical TV series and to explore how violence or aggression towards healthcare providers is portrayed in these settings.",[257,258,259,260],"End of Life Care","Violent Aggressive Behavior","Television Viewing","Media Use",[262,263,264,265,266],"violence","aggression","death","dying","medical tv shows","2026-02-10",{"date":269,"type":37},"2026-02-18",{"date":271,"type":22},"2026-05-10",{"date":273,"type":22},"2027-12",{"name":43,"class":44},2,{"id":277,"slug":278,"hasResults":12,"nctId":279,"briefTitle":280,"officialTitle":281,"acronym":4,"eligibilityCriteria":282,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":283,"enrollmentInfo":284,"targetDuration":4,"studyType":23,"phases":285,"briefSummary":286,"conditions":287,"keywords":289,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":293,"lastUpdatePostDateStruct":294,"startDateStruct":296,"completionDateStruct":298,"leadSponsor":300,"locationsCount":45},"100622138","brief-intervention-for-fcd-a-feasibility-study-100622138","NCT07379723","Brief Intervention for FCD: A Feasibility Study","Feasibility Pilot Study of a Brief Intervention in Functional Cognitive Disorder","Inclusion Criteria:\n\n* Adults aged 65 or below\n* Meet criteria for diagnosis of FCD (criteria include normal MRI results with no neurological diagnosis, and symptoms that are not explained by any other medical condition, performance at routine pre-baseline neuropsychological assessment within the service)\n* Not taking part in any other intervention study or trial\n\nExclusion Criteria:\n\n* Aged above 65 years\n* Lack capacity to consent\n* MRI results not in normal range\n* Neurological diagnosis\n* Indication of severe low mood or depression (from clinical interview, routine measures)\n* Taking part in any other intervention study or trial","65 Years",{"count":207,"type":22},[25],"The goal of this study is to learn if a single session intervention for people with Functional Cognitive Disorder (FCD) is feasible and acceptable. The main questions it aims to answer are:\n\nWhat is the impact of a single session intervention on FCD symptoms, functional impairment, and quality of life in people with FCD?\n\nWhat is the feasibility and acceptability of piloting a single session intervention for people with FCD.\n\nParticipants will:\n\n* Complete questionnaires about cognitive concerns, anxiety, depression, functional impairment and quality of life\n* Visit the clinic for a single session intervention including practicing the Attention Training Technique (ATT)\n* Complete 2 telephone calls with a researcher to discuss their use of the intervention and to complete the same questionnaires from their clinic visit, and a questionnaire about their experience of the study and intervention.",[288],"Functional Cognitive Disorder",[288,290,164,291,292],"Brief Interventions","Pilot","Attention Training","2026-01-23",{"date":295,"type":37},"2026-01-30",{"date":297,"type":37},"2025-11-11",{"date":299,"type":22},"2026-05-01",{"name":43,"class":44},{"id":302,"slug":303,"hasResults":12,"nctId":304,"briefTitle":305,"officialTitle":306,"acronym":307,"eligibilityCriteria":308,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":309,"targetDuration":4,"studyType":23,"phases":310,"briefSummary":311,"conditions":312,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":314,"lastUpdatePostDateStruct":315,"startDateStruct":317,"completionDateStruct":319,"leadSponsor":321,"locationsCount":275},"100544671","immunometabolism-of-machine-perfusion-strategies-100544671","NCT06371924","Immunometabolism of Machine Perfusion Strategies","Mechanistic Evaluation of Machine Perfusion Strategies in Donation After Circulatory Death Liver Transplantation","iMaps","Inclusion Criteria Donor inclusion criteria\n\n1. DCD category III donors considered for abdominal organs-only retrieval.\n2. Donor age ≥18 years.\n3. Retrieval procedure allocated to KCH or UHB NORS teams.\n4. Donor liver accepted for a patient at KCH or UHB transplant waiting list via the standard offering process.\n5. Functional donor warm ischaemia (defined as a period between the systolic blood pressure \\\u003C50mmHg and aortic cold flush) ≤30 minutes.\n6. Donor BMI \\\u003C35kg\u002Fm2.\n7. Predicted cold ischaemic time \\\u003C8 hours.\n8. Donor family has given consent to use donated liver for research.\n\nTransplant recipient inclusion criteria\n\n1. Recipients 18 years of age or older.\n2. Listed on an elective transplant waiting list.\n3. First liver transplantation.\n4. Suitable to receive a DCD graft based on the liver listing MDT.\n5. Willingness to consent for the study participation.\n\nExclusion Criteria Donor exclusion criteria\n\n1. Donor is HIV, hepatitis B (HBV HbsAg) or hepatitis C (HCV RNA) positive. HBV anti-Hbc positive donors are acceptable.\n2. Macroscopic evidence of fibrosis.\n3. Liver weight \\>2.5 kg.\n4. Retrieval of cardiothoracic organs intended for transplantation.\n5. Any medical condition that, in the opinion of the principal investigator, would interfere with safe completion of the trial.\n\nTransplant recipient exclusion criteria\n\n1. High-risk surgical candidates (i.e. presence of extensive portomesenteric thrombosis, previous complex upper abdominal surgery).\n2. Patients receiving super-urgent transplantation for acute and acute-on-chronic liver failure.\n3. Patients unable to give full informed consent.",{"count":125,"type":22},[25],"There are not enough donated livers for everybody who needs one, and as a result, thousands of patients worldwide are waiting for liver transplants, with many dying while waiting for a life-saving organ. One reason for this shortage is that some usable livers from donors who are considered of high risk are being thrown away out of concern that they might not work well after transplantation due to a problem called ischaemia reperfusion injury (IRI).\n\nThe discarded organs are mostly those coming from donors who have died due to cardiac arrest (called 'donation after circulatory death' or DCD), with only 27% of them being used in the UK. The quality of these DCD organs could be improved by changing how they are preserved after being removed from the donor. The most commonly used strategy is still to remove the livers and put them in an icebox ('static cold storage' or SCS). The alternative approaches, which are more complex and expensive, but that can also improve the quality of the DCD livers, involve using machines to pump fluids through the livers ('machine perfusion' or MP).\n\nThere are three MP methods being used in patients: 1) normothermic regional perfusion (NRP), which involves pumping the donor's blood through the liver after the donor has died but the liver is still in the donor's body; 2) normothermic machine perfusion (NMP), in which the liver is pumped with blood outside of the donor's body; and 3) hypothermic machine perfusion (HOPE), which is also used outside of the donor's body by pumping cold fluid into the liver. HOPE and NRP have been shown to improve how well DCD livers function after transplantation. NMP can also improve the quality of the DCD livers, but its main advantage is that it allows confirming that the donated liver functions well before proceeding with the transplant. Until now, there has not been a proper comparison of these methods, and the doctors do not understand well the mechanisms through which MP improves the quality of the DCD livers.\n\nThe iInvestigators plan to conduct a study where 36 DCD human livers will be split into three groups: SCS, NRP, and HOPE. After that, they will be put in NMP to confirm that they are good enough to be transplanted and to study the mechanisms through which NRP, SCS and HOPE work.",[313],"Liver Transplantation","2025-08-08",{"date":316,"type":37},"2025-08-13",{"date":318,"type":37},"2025-02-17",{"date":320,"type":22},"2026-05-31",{"name":43,"class":44},{"id":323,"slug":324,"hasResults":12,"nctId":325,"briefTitle":326,"officialTitle":326,"acronym":327,"eligibilityCriteria":328,"healthyVolunteers":182,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":329,"targetDuration":4,"studyType":186,"phases":4,"briefSummary":331,"conditions":332,"keywords":336,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":338,"lastUpdatePostDateStruct":339,"startDateStruct":341,"completionDateStruct":343,"leadSponsor":345,"locationsCount":45},"100581825","prospective-ocular-imaging-for-intracranial-pressure-evaluation-100581825","NCT06855342","Prospective Ocular Imaging for Intracranial Pressure Evaluation","POICCP","Healthy controls:\n\nInclusion Criteria:\n\n1. Aged ≥18 years\n2. Presumed normal ICP undergoing routine mydriatic ophthalmology OCT scans.\n\nExclusion Criteria:\n\n1. Significant media opacity restricting acquisition of retinal vein imaging and video capture in both eyes.\n2. Current or previous evidence of glaucoma, glaucoma suspect, family history of glaucoma in a 1st degree relative, or non-glaucoma related optic neuropathy in both eyes.\n3. Retinal vein or artery occlusions in both eyes (branch or central).\n4. Active or history of proliferative diabetic retinopathy, or diabetic papillitis in both eyes.\n5. Symptoms and\u002For signs that, in the opinion of the investigator, indicate possible raised intracranial pressure.\n6. Current or previous history of disorders affecting intracranial pressure including, but not limited to, idiopathic intracranial hypertension, hydrocephalus, epilepsy, intracranial bleeds, space occupying lesions or tumours, traumatic brain injury, central nervous system inflammatory or infectious disorders, congenital neuro-cranial disorders, neurosurgical or interventional procedures. Radiologically-confirmed ischaemic stroke is permissible, provided the patient did not develop a subsequent haemorrhagic stroke or require neurosurgical intervention.\n7. Current or recent (6 months) history of medication use affecting intracranial pressure including steroids, vitamin A analogues, tetracyclines, recombinant growth hormone, lithium, nitrofurantoin, nalidixic acid, sulfenazone, cyclosporine, amiodarone.\n8. Bed-bound patients.\n9. Patients who, in the opinion of the investigator, would be unwilling or unable to provide written informed consent, or undergo the testing procedures as described in the protocol.\n\nPatients due to undergo lumbar puncture or intracranial pressure bolt monitoring:\n\nInclusion:\n\n1. Aged ≥18 years.\n2. Patients due to undergo lumbar puncture with measurement of Opening and Closing CSF pressures\n3. Patients due to undergo continuous ICP monitoring\n\nExclusion:\n\n2\\. Current or previous evidence of glaucoma or glaucoma suspect in both eyes.\n\n3\\. Retinal vein or artery occlusions in both eyes (branch or central).\n\n4\\. Bed-bound patients.\n\n5\\. Patients who, in the opinion of the investigator, would be unwilling or unable to provide written informed consent, or undergo the testing procedures as described in the protocol.",{"count":330,"type":22},160,"This is a prospectively recruiting, database development study collecting images and videos of the spontaneous venous pulsation at the back of people's eyes - this is a pulse one can see on examination of the back of the eye, originating from the blood vessels around the nerve that connects the eye to the brain (the optic nerve), and is present in most people who have normal pressure around the brain. However, in people with raised pressure in the brain, this pulse disappears as the pressure rises. Many things can cause the pressure around the brain to increase, including tumours, swellings and trauma. The investigators want to test if high-quality images and videos of this pulse, taken using both hand-held and larger, fixed-platform machines, can be used to train a software tool to automatically detect this pulse. The investigators want to collect these images and videos in 2 groups of patients: those with no known or suspected brain pressure problems, and those who are suspected to have raised pressure and\u002For are due to undergo measurement of the pressure around the brain, called lumbar punctures or intracranial pressure bolt monitoring. These tests to check the pressure around the brain are invasive - they involve inserting needles in the back or directly into the brain to measure the pressure, and carry risks. The value of these two groups of people will be to help train the software to reasonably say whether a pulse is present or absent and, hopefully, estimate what the pressure around the brain may be without the need for an invasive test.",[333,334,335],"Idiopathic Intracranial Hypertension","Intracranial Pressure Increase","Spontaneous Venous Pulsations",[335,337],"Optic disc videography","2025-08-01",{"date":340,"type":37},"2025-08-03",{"date":342,"type":37},"2025-01-10",{"date":344,"type":22},"2025-11-30",{"name":43,"class":44},{"id":347,"slug":348,"hasResults":12,"nctId":349,"briefTitle":350,"officialTitle":351,"acronym":4,"eligibilityCriteria":352,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":353,"targetDuration":4,"studyType":186,"phases":4,"briefSummary":355,"conditions":356,"keywords":358,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":338,"lastUpdatePostDateStruct":361,"startDateStruct":363,"completionDateStruct":365,"leadSponsor":367,"locationsCount":45},"100518849","novel-erg-for-detection-of-hydroxychloroquine-retinopathy-100518849","NCT06035887","Novel ERG for Detection of Hydroxychloroquine Retinopathy","A Feasibility Study Using Novel, Portable Electroretinography Devices to Detect Hydroxychloroquine Retinopathy","Inclusion Criteria:\n\n1. Age ≥18 years\n2. HCQ groups:\n\n   a. HCQ use \\>5 years for patients without any high-risk factors, or \\>1 year in patients with one or more high-risk factors for HCQ retinopathy, namely: i. Dose \\>5mg\u002Fkg per day actual body weight (ABW) ii. Estimated glomerular filtration rate (eGFR) of \\\u003C60mls\u002Fmin\u002F1.73m2 iii. Concomitant tamoxifen use\n3. Control group:\n\n   1. No prior HCQ exposure\n\nExclusion Criteria:\n\n1. Cataract grade ≥3 of any subtype\n2. Recent cataract surgery within 4 weeks of recruitment\n3. Significant media opacity or corneal disease including, but not limited to, corneal oedema, corneal scarring, keratoconus, previous corneal transplants, severe keratoconjunctivitis sicca (requiring the use of topical serum, immunosuppressive or analogous therapy, or procedural treatment).\n4. Significant macular co-pathology including, but not limited to, macular degeneration, macular scarring, cystic macular oedema (for any reason), staphyloma.\n5. Inherited retinal and\u002For macular dystrophies including colour vision deficiencies\n6. Active or previous posterior uveitis or pan-uveitis\n7. Aphakia\n8. High refractive error \\>6.00 dioptres\n9. Amblyopia\n10. Diabetes\n11. Retinal angiopathies including, but no limited to, retinal vein occlusion, retinal artery occlusion, ocular ischaemic syndrome, HIV retinopathy, Sickle cell disease, radiation retinopathy\n12. Visually significant surgical retinal disease including epiretinal membrane, macular hole, retinal detachment, retinal tear\n13. Previous retinal laser or intravitreal treatment\n14. Moderate or worse glaucoma\n15. Optic atrophy\n16. Photosensitive epilepsy\n17. Ungradable HCQ retinopathy screening images\n18. Periocular infection or rash (recruitment can be deferred until acute pathology has resolved)\n19. Unable or unwilling to undertake study activities\n20. Any active use or history of the following medications:\n\nAmiodarone Canthaxanthin Deferoxamine Digoxin Ethambutol Interferon-alpha Melatonin Nefazodone Sildenafil Vigabatrin Chloroquine Quinine",{"count":354,"type":22},140,"The purpose of the study is to investigate novel electroretinography (ERG) devices in the detection of hydroxychloroquine retinopathy. Two devices (the RETEval full-field and flicker ERG and UTAS multifocal ERG) will be evaluated in this study, comparing device outputs to standard of care screening tests, in groups of participants characterised by presence or absence of hydroxychloroquine-related retinopathy.",[357],"Hydroxychloroquine Retinopathy",[359,360],"Electroretinography","Diagnostic Evaluation",{"date":362,"type":37},"2025-08-06",{"date":364,"type":37},"2024-05-31",{"date":366,"type":22},"2026-05",{"name":43,"class":44},{"id":369,"slug":370,"hasResults":12,"nctId":371,"briefTitle":372,"officialTitle":373,"acronym":4,"eligibilityCriteria":374,"healthyVolunteers":12,"sex":83,"minAge":19,"maxAge":4,"enrollmentInfo":375,"targetDuration":4,"studyType":186,"phases":4,"briefSummary":377,"conditions":378,"keywords":380,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":382,"lastUpdatePostDateStruct":383,"startDateStruct":385,"completionDateStruct":387,"leadSponsor":389,"locationsCount":45},"100597764","pelvic-floor-exercises-for-suboptimal-anorectal-manometry-100597764","NCT07062731","Pelvic Floor Exercises for Suboptimal Anorectal Manometry","Effect of Pelvic Floor Muscle Exercises on Women With Suboptimal Anorectal Manometry Results After an Obstetric Anal Sphincter Injury (OASI)","Inclusion Criteria:\n\n1. Female patients who have sustained an obstetric anal sphincter injury after their most recent delivery and:\n\n   1. Are at least 6 weeks postpartum\n   2. Has not received any form of guided pelvic floor exercises by a licensed women's health physiotherapist postpartum\n2. Either able to speak, read and write in English, or has a professional interpreter present at the time of appointment.\n3. Capable of understanding and signing the informed consent form after full discussion of the investigations and its risks and benefits.\n4. Able and willing to complete the St Mark's Score, ICIQ-UI SF and other trial related questionnaires, comply with scheduled clinic visits and manometry studies.\n\nExclusion Criteria:\n\n* Inclusion Criteria\n\n  1. Female patients who have sustained an obstetric anal sphincter injury after their most recent delivery and:\n\n     1. Are at least 6 weeks postpartum\n     2. Has not received any form of guided pelvic floor exercises by a licensed women's health physiotherapist postpartum\n  2. Either able to speak, read and write in English, or has a professional interpreter present at the time of appointment.\n  3. Capable of understanding and signing the informed consent form after full discussion of the investigations and its risks and benefits.\n  4. Able and willing to complete the St Mark's Score, ICIQ-UI SF and other trial related questionnaires, comply with scheduled clinic visits and manometry studies.\n\nExclusion Criteria\n\n1. Women who have sustained an obstetric anal sphincter injury more than a year ago\n2. Women who have had another vaginal delivery after sustaining an obstetric anal sphincter injury in a previous delivery.\n3. Existing anal pain precluding anorectal examination\n4. Existing neurological, musculoskeletal disorders which impedes ability to perform pelvic floor muscle exercises\n5. Age \\\u003C18 years old\n6. Currently pregnant\n7. Inability to comply with pelvic floor muscle exercises",{"count":376,"type":22},50,"Currently, guidelines from the Royal College of Obstetricians and Gynaecologists stipulate that all women who have sustained an obstetric anal sphincter injury in a previous pregnancy and who are symptomatic or have abnormal endoanal ultrasonography and\u002F or manometry should be counselled regarding the option of an elective Caesarean section. An abnormal endoanal ultrasonography is currently considered to be a defect of the external anal sphincter (EAS) of more than 30 degrees while an abnormal anorectal manometry would be an incremental squeeze pressure of less than 20mmHg.\n\nThis study aims to evaluate if a course of guided pelvic floor exercises could improve anal sphincter function on those with suboptimal or abnormal anal incremental squeeze pressures, and subsequently expand their options for future modes of delivery (vaginal delivery not contraindicated)",[379],"Obstetric Anal Sphincter Injury",[381],"pelvic floor muscle exercises","2025-07-03",{"date":384,"type":37},"2025-07-14",{"date":386,"type":37},"2025-06-15",{"date":388,"type":22},"2027-09-15",{"name":43,"class":44},{"id":391,"slug":392,"hasResults":12,"nctId":393,"briefTitle":394,"officialTitle":395,"acronym":396,"eligibilityCriteria":397,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":398,"enrollmentInfo":399,"targetDuration":4,"studyType":23,"phases":401,"briefSummary":402,"conditions":403,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":412,"lastUpdatePostDateStruct":413,"startDateStruct":415,"completionDateStruct":417,"leadSponsor":419,"locationsCount":45},"100541215","reducing-chronic-breathlessness-in-adults-by-following-a-self-guided-internet-based-supportive-intervention-self-breathe-100541215","NCT06326957","Reducing Chronic Breathlessness in Adults by Following a Self-guided, Internet Based Supportive Intervention (SELF-BREATHE)","A Multicentre, Randomised Controlled Trial Comparing Usual NHS Care to a Self-guided Internet-based Intervention (SELF-BREATHE) Plus Usual NHS Care to Reduce Breathlessness in Adults Living With Chronic Breathlessness","SELF-BREATHE","Inclusion Criteria:\n\n* Adults ≥ 18 years of age\n* Chronic Breathlessness at rest and \u002F or exertion\n* Chronic Breathlessness (CB) defined as breathlessness that persists (\\>3months) despite pharmacological treatment of the underlying disease including, but not limited to; cancer, chronic obstructive pulmonary disease (COPD), interstitial lung disease (ILD), bronchiectasis, chronic fibrotic lung disease following SARS-CoV2 infection\n* Medical Research Council (MRC) dyspnea score ≥ 2 (MRC 2= short of breath when hurrying on the level or walking up a slight hill\n* Availability to a computer, tablet, or smart phone with internet access\n* Able to provide informed consent.\n\nExclusion Criteria:\n\n* Breathlessness of unknown cause\n* Primary diagnosis of chronic hyperventilation syndrome\n* Currently participating in a rehabilitation programme e.g.,pulmonary\u002Fcardiac rehabilitation (patients that have completed PR \\>4-weeks will be eligible).","110 Years",{"count":400,"type":22},246,[25],"Background:\n\nSome health conditions make breathing difficult and uncomfortable. When this happens every day, it is called chronic breathlessness. Over 3 million people living with heart and lung disease have chronic breathlessness in the UK.\n\nBreathlessness is very difficult for patients themselves and their families, resulting in disability and feelings of fear, distress, and isolation. Due a to lack of supportive breathlessness services many patients frequently attend hospital Accident and Emergency (A\\&E) departments seeking help.\n\nGiven the on-going challenges faced by the National Health Service (NHS) in the United Kingdom, such as long waiting times, staff shortages, increased demand for services because of the COVID-19 pandemic, there is an urgent need to develop new ways to support those living with chronic breathlessness. One potential solution is to offer support online, as it is estimated that in the UK, 7 out of every 10 people with chronic breathlessness are internet users.\n\nWith the help of patients and NIHR funding the research team lead by Dr Charles Reilly, developed an online breathlessness supportive website called SELF-BREATHE. SELF-BREATHE provides information and self-management tools such as breathing exercises, that patients can do at home themselves.\n\nSELF-BREATHE has been tested as part of its development. SELF-BREATHE is acceptable and valued by patients. But what is unknown is whether SELF-BREATHE improves patients' breathlessness and their life? This is the question this research seeks to answer.\n\nAims\n\n1. To test if using SELF-BREATHE for six-weeks improves patients' breathlessness, their quality of life and whether SELF-BREATHE should be offered within the NHS\n2. To see if patients opt to continue to use SELF-BREATHE after six-weeks and what benefits this may have for patients.\n\nMethods\n\nThe research team are undertaking a randomised controlled trial. For this, 246 people living with chronic breathlessness will be recruited in to this study. Each person will be randomly chosen by a computer to continue with their usual care or their usual care plus access to SELF-BREATHE. All study participants will complete questionnaires at the start of the study, thereafter at seven and twelve weeks after randomisation.\n\nThese questionnaires will ask patients about 1) their breathlessness and its effect on their life and 2) planned and unplanned hospital visits. At the end of the study, we will compare answers to these questionnaires between the two groups at seven and 12 weeks.\n\nThis will tell if SELF-BREATHE improved patients' breathlessness and reduced their need for unplanned hospital visits e.g., A\\&E attendances due to breathlessness.",[404,405,406,407,408,409,410,411],"Chronic Obstructive Pulmonary Disease","Bronchiectasis","Interstitial Lung Disease","Lung Cancer","Asthma","Dyspnea","Fibrotic Lung Disease","Chronic Lung Disease","2025-06-10",{"date":414,"type":37},"2025-06-13",{"date":416,"type":37},"2024-07-04",{"date":418,"type":22},"2028-07",{"name":43,"class":44},{"id":421,"slug":422,"hasResults":12,"nctId":423,"briefTitle":424,"officialTitle":425,"acronym":426,"eligibilityCriteria":427,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":428,"enrollmentInfo":429,"targetDuration":431,"studyType":186,"phases":4,"briefSummary":432,"conditions":433,"keywords":435,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":440,"lastUpdatePostDateStruct":441,"startDateStruct":443,"completionDateStruct":444,"leadSponsor":446,"locationsCount":45},"100586698","development-of-a-cough-control-questionnaire-ccq-100586698","NCT06918756","Development of a Cough Control Questionnaire (CCQ)","The Development and Validation of a Cough Control Questionnaire","CCQ","Inclusion Criteria:\n\n* Adult patients aged 18 and over with acute and chronic cough (including refractory chronic cough and unexplained chronic cough) and able to read and write in English. A smaller number (n =20) of healthy volunteers will also be included with no evidence of significant respiratory disease.\n\nExclusion Criteria:\n\n* Current smokers (or smoking within the last 12 months), respiratory tract infection within the last 4 weeks, use of angiotensin converting enzyme inhibitors (ACEi), and pregnancy","100 Years",{"count":430,"type":22},100,"7 Years","Chronic cough (\\>8 weeks in duration) affects 5-12% of the global population, and is associated with considerable health status impairment and comorbidities. Currently, there are validated severity and impact outcome measures whilst objective measures with cough frequency monitoring is not available in routine clinical practice. Unlike other chronic respiratory diseases, namely asthma, there are no validated dedicated tools to assess the control of cough as a disease.\n\nThis study aims to develop a validated patient-focused tool to assess the control of cough, which may be useful to evaluate the benefit and value of treatments in both clinical and research settings.",[434],"Cough",[436,437,438,439],"patient-reported outcomes","cough","control","questionnaire","2025-04-01",{"date":442,"type":37},"2025-04-09",{"date":440,"type":37},{"date":445,"type":22},"2031-09-01",{"name":43,"class":44},{"id":448,"slug":449,"hasResults":12,"nctId":450,"briefTitle":451,"officialTitle":452,"acronym":453,"eligibilityCriteria":454,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":455,"targetDuration":4,"studyType":186,"phases":4,"briefSummary":456,"conditions":457,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":440,"lastUpdatePostDateStruct":461,"startDateStruct":463,"completionDateStruct":465,"leadSponsor":467,"locationsCount":45},"100586567","renal-perfusion-and-the-development-of-aki-following-traumatic-injury-100586567","NCT06917053","Renal Perfusion and the Development of AKI Following Traumatic Injury","Renal Perfusion and the Development of AKI Following Traumatic Injury - A Longitudinal Observational Cohort Study","PERTAKI","Inclusion Criteria:\n\n* Age \\> 18 years\n* Within 24 hours of ICU admission following traumatic injury\n* Received any blood products during initial resuscitation\n* Lactate \\> 2 mmol\u002Fl at any stage prior to study enrolment\n\nExclusion Criteria:\n\n* Known intolerance to Sonovue or any other ultrasound contrast agent\n* Patients with un-survivable injuries \u002F not expected to survive 24 hours in whom the intent of treatment is palliative\n* Known CKD 4 or end stage renal failure\n* Pregnancy",{"count":21,"type":22},"Acute kidney injury (AKI) is a complication of traumatic haemorrhagic shock (THS) and together these conditions increase mortality risk. Although septic shock patients who develop severe AKI are known to develop hypoperfusion of the renal cortex, little is known regarding intra-renal perfusion changes in THS. The aim of the current study is to investigate the effects of THS on renal microcirculatory perfusion.",[458,459,460],"Traumatic Haemorrhagic Shock","AKI (Acute Kidney Injury) Due to Trauma","AKI - Acute Kidney Injury",{"date":462,"type":37},"2025-04-08",{"date":464,"type":37},"2024-04-13",{"date":466,"type":22},"2026-07",{"name":43,"class":44},{"id":469,"slug":470,"hasResults":12,"nctId":471,"briefTitle":472,"officialTitle":473,"acronym":474,"eligibilityCriteria":475,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":476,"targetDuration":4,"studyType":23,"phases":478,"briefSummary":479,"conditions":480,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":440,"lastUpdatePostDateStruct":483,"startDateStruct":485,"completionDateStruct":487,"leadSponsor":488,"locationsCount":45},"100534112","the-effect-of-vasopressor-therapy-on-renal-perfusion-in-septic-shock-100534112","NCT06234592","The Effect of Vasopressor Therapy on Renal Perfusion in Septic Shock","The Effect of Vasopressor Therapy on Renal Perfusion in Patients With Septic Shock - a Mechanistically Focussed Randomized Control Study","REPERFUSE","Inclusion Criteria:\n\n* Within 48 hours of intensive care admission\n* Evidence of suspected or confirmed infection\n* Sequential Organ Failure (SOFA) score increase of 2 or more (assuming a baseline of 0 if no previous measures)\n* Requirement for norepinephrine infusion as the sole vasopressor agent in a dose of \\>0.1mcg\u002Fkg\u002Fmin\n* Lactate \\>2mmol\u002FL at any stage prior to randomisation\n\nExclusion Criteria:\n\n* Known intolerance to Sonovue™ contrast medium, vasopressin or angiotensin II\n* Patients receiving other vasoactive drugs in addition to norepinephrine\n* Patients with known chronic kidney disease (CKD) stage 4 or 5 (baseline glomerular filtration rate (GFR) \\\u003C30mls\u002Fmin)\n* Patients receiving extra corporal membrane oxygenation (ECMO)\n* Patients with acute occlusive coronary syndromes requiring intervention\n* Patients with mesenteric ischaemia\n* Patients with a history or presence of aortic dissection or abdominal aortic aneurysm\n* Patients with Raynaud's syndrome or acute vaso-occlusive conditions\n* Pregnancy",{"count":477,"type":22},45,[25],"Acute kidney injury (AKI) is a common complication of septic shock and together these conditions carry a high mortality risk. In septic patients who develop severe AKI renal cortical perfusion is deficient despite normal macrovascular organ blood flow. This intra-renal perfusion abnormality may be amenable to pharmacological manipulation, which may offer mechanistic insight into the pathophysiology of septic AKI. The aim of the current study is to investigate the effects of vasopressin and angiotensin II on renal microcirculatory perfusion in a cohort of patients with septic shock.",[481,482],"Septic Shock","Acute Kidney Injury",{"date":484,"type":37},"2025-04-04",{"date":486,"type":37},"2024-01-05",{"date":466,"type":22},{"name":43,"class":44},{"id":490,"slug":491,"hasResults":12,"nctId":492,"briefTitle":493,"officialTitle":494,"acronym":4,"eligibilityCriteria":495,"healthyVolunteers":12,"sex":18,"minAge":53,"maxAge":496,"enrollmentInfo":497,"targetDuration":4,"studyType":23,"phases":499,"briefSummary":500,"conditions":501,"keywords":504,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":508,"lastUpdatePostDateStruct":509,"startDateStruct":511,"completionDateStruct":513,"leadSponsor":515,"locationsCount":45},"100571363","optimising-hfovtv-in-newborn-infants-100571363","NCT06719284","Optimising HFO&VTV in Newborn Infants","Crossover Study of the Cerebral Blood Flow and Cardiac Output At Different Targeted Tidal Volumes During High Frequency Oscillation with Volume Targeted Ventilation (HFO&VTV)","Inclusion Criteria:\n\n-Newborn infants of any gestation receiving high frequency oscillatory ventilation\n\nExclusion Criteria:\n\n* Infants with known intracerebral pathology (stroke, hydrocephalus, intracerebral hemorrhage, severe hypoxic ischemic encephalopathy).\n* Infants with congenital cardiac abnormalities.","1 Year",{"count":498,"type":22},27,[25],"Mechanical ventilation (MV) is life saving for infants requiring respiratory support in the newborn period but its use has been associated with complications. High frequency oscillation (HFO) is a type of MV that delivers small volumes of gas across the lungs at fast frequencies. HFO is a lung protective strategy but it has also been linked to brain injury due to low carbon dioxide tensions. High-frequency oscillation with volume-targeted ventilation (HFO\\&VTV) is a new mode of HFO in which the clinician sets a target volume of gas to be delivered to the lungs at fast rates to decrease the lung injury related to the ventilator. Further, HFO\\&VTV achieves better control of carbon dioxide levels and may therefore protect against brain injury. Currently, there are no written guidelines about the use of HFO\\&VTV. This study aim to determine the safety profile of HFO\\&VTV compared to HFO by comparing the velocity of blood flow to the brain in term born infants and the cardiac output in term and preterm infants during the two modes. The investigators will also determine the optimum starting value of the target tidal volume during HFOV\\&VTV. Infants will be studied at three different target tidal volumes for a period of 10-20 minutes each. A cranial ultrasound (for term infants only) and bedside echocardiogram will be performed at the end of each period.",[502,503],"High Frequency Oscillation","Volume Targeted Ventilation",[505,506,507],"high frequency oscillation","volume targeted ventilation","newborn infant","2025-03-05",{"date":510,"type":37},"2025-03-10",{"date":512,"type":37},"2025-02-26",{"date":514,"type":22},"2026-09-01",{"name":43,"class":44},{"id":517,"slug":518,"hasResults":12,"nctId":519,"briefTitle":520,"officialTitle":520,"acronym":521,"eligibilityCriteria":522,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":523,"targetDuration":4,"studyType":23,"phases":525,"briefSummary":526,"conditions":527,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":529,"lastUpdatePostDateStruct":530,"startDateStruct":532,"completionDateStruct":534,"leadSponsor":536,"locationsCount":4},"100577832","ai-powered-portable-mri-abnormality-detection-100577832","NCT06803420","AI-powered Portable MRI Abnormality Detection","APPMAD","Inclusion Criteria:\n\nAdults ≥18 years old. Undergoing standard brain MRI including T2-weighted sequences.\n\nExclusion Criteria:\n\nContraindications to MRI (e.g. pacemaker, pregnancy). Poor quality MRI scans without a neuroradiology report.",{"count":524,"type":22},400,[25],"This study aims to test a new AI-powered portable MRI scanner that can quickly identify whether a brain scan is normal or abnormal. Currently, standard MRI scans are expensive and have long waiting times. Our goal is to see if a smaller, cheaper, and more accessible MRI scanner-combined with artificial intelligence (AI)-can help doctors identify abnormalities faster and improve patient care.\n\nWe will invite patients from King's College Hospital (KCH) who are already having a standard MRI scan. They will be asked to have an extra scan using the portable MRI, which takes about 60 minutes. The AI tool will then analyse these scans and compare its results to those of expert radiologists.\n\nBy the end of the study, we hope to prove whether portable MRI with AI can be used in hospitals and GP clinics, making brain scans more accessible, reducing wait times, and helping doctors prioritise urgent cases.\n\nThis study is funded by the Medical Research Council (MRC) and has been approved by UK research ethics committees.",[528],"Head Injury","2025-01-27",{"date":531,"type":37},"2025-01-31",{"date":533,"type":22},"2025-02-01",{"date":535,"type":22},"2027-10",{"name":43,"class":44},{"id":538,"slug":539,"hasResults":12,"nctId":540,"briefTitle":541,"officialTitle":542,"acronym":4,"eligibilityCriteria":543,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":544,"targetDuration":4,"studyType":186,"phases":4,"briefSummary":546,"conditions":547,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":549,"lastUpdatePostDateStruct":550,"startDateStruct":552,"completionDateStruct":554,"leadSponsor":555,"locationsCount":45},"100411725","clinical-outcome-modelling-of-rapid-dynamics-in-acute-stroke-100411725","NCT04641286","Clinical Outcome Modelling of Rapid Dynamics in Acute Stroke","Clinical Outcome Modelling of Rapid Dynamics in Acute Stroke With Joint-detail, Remote, Body Motion Analysis","Inclusion Criteria:\n\n* Putative diagnosis of an acute stroke\n* Admission on the stroke unit\n\nExclusion Criteria:\n\n* Under 18 years of age",{"count":545,"type":22},8000,"Stroke - still the second commonest cause of death and principal cause of adult neurological disability in the Western World - is characterised by rapid changes over time and marked variability in outcomes. A patient may improve or deteriorate over minutes, and the resultant disability may range from an obvious complete paralysis to subtle, task dependent incoordination of a single limb.\n\nUnlike many other neurological disorders, stroke can be exquisitely sensitive to prompt and intelligently tailored treatment, rewarding innovation in the delivery of care with real-world, tangible impact on patient outcomes. Optimal treatment therefore requires both detailed characterisation of the patient's clinical picture and its pattern of change over time.\n\nArguably the most important aspect of the patient's clinical picture -- body movement -- remains remarkably poorly documented: quantified only subjectively and at infrequent intervals in the patient's clinical evolution. The combination of artificial intelligence with high-performance computing now enables automatic extraction of a patient's skeletal frame resolved down to major joints, like that of a stick-man, to be delivered simply, safely, and inexpensively, without the use of cumbersome body worn markers. Central to this technology is patient privacy, with the skeletal frame extracted in real time, ensuring no video data, from which patients can be identified, to be stored or transmitted by the device.\n\nOur motion categorisation system -- MoCat -- will be used to study the rapid dynamics of acute stroke, seamlessly embedded in the clinical stream. By quantifying the change in motor deficit over time we shall examine the relationship between these trajectories with clinical outcomes and develop predictive models that can support clinical management and optimise service delivery.",[548],"Stroke","2024-10-22",{"date":551,"type":37},"2024-10-24",{"date":553,"type":37},"2021-07-07",{"date":173,"type":22},{"name":43,"class":44},{"id":557,"slug":558,"hasResults":12,"nctId":559,"briefTitle":560,"officialTitle":561,"acronym":562,"eligibilityCriteria":563,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":564,"targetDuration":4,"studyType":23,"phases":566,"briefSummary":567,"conditions":568,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":571,"lastUpdatePostDateStruct":572,"startDateStruct":574,"completionDateStruct":576,"leadSponsor":578,"locationsCount":45},"100520215","mos-fed-mosaicism-in-focal-epilepsy-cortical-dysplasia-tissue-100520215","NCT06053671","Mos-FED (Mosaicism in Focal Epilepsy Cortical Dysplasia Tissue)","Dissecting mTOR Pathway Mosaicism in FCDII-Harbouring Epileptic Brain and Peripheral Tissue.","MosFED","Epilepsy in Focal Cortical Dysplasia Type IIA\u002FB\n\nKey Inclusion Criteria:\n\n1. Adult and Paediatric Patients (male and female)\n2. A histologically proven diagnosis of FCDIIA\u002FB or a suspected diagnosis of FCDIIA\u002FB (on MRI\u002FEEG and PET grounds) awaiting resective Epilepsy surgery.\n3. Able to attend appointment\u002Fhospital and undergo sampling of serum and nasal swab\n4. Informed Consent Available\n\n   Key Exclusion Criteria:\n5. Any acute or chronic conditions that could limit the ability of the patient to participate in the study.\n6. Refusal to give informed consent.",{"count":565,"type":22},60,[25],"Focal cortical dysplasia (FCD) is a malformation of brain development, the most common cause of drug-resistant epilepsy and often caused by mutations in mammalian target of rapamycin (mTOR) pathway genes. Patients with FCD develop drug-resistant seizures. This study will look at FCD tissue removed during epilepsy surgery and aims to detect mutations in mTOR pathway genes in brain cells. Secondly, the investigators will establish if evidence of mutations found in brain cells can also be detected as circulating free DNA (cfDNA) in blood. By looking at which genes are made into proteins in individual cells found in epilepsy surgical tissue (single cell expression profiling),the investigators will attempt to identify new genetic targets in FCD.\n\nThe main outcome will be finding new causes of epilepsy with FCD and the development of new diagnostic and screening tools.",[569,570],"Focal Cortical Dysplasia","Epilepsy","2024-10-21",{"date":573,"type":37},"2024-10-23",{"date":575,"type":37},"2023-04-09",{"date":577,"type":22},"2026-04-08",{"name":43,"class":44},{"id":580,"slug":581,"hasResults":12,"nctId":582,"briefTitle":583,"officialTitle":584,"acronym":4,"eligibilityCriteria":585,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":586,"targetDuration":4,"studyType":23,"phases":588,"briefSummary":589,"conditions":590,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":571,"lastUpdatePostDateStruct":593,"startDateStruct":594,"completionDateStruct":596,"leadSponsor":598,"locationsCount":45},"100441589","optimising-ventilation-in-preterms-with-closed-loop-oxygen-control-100441589","NCT05030337","Optimising Ventilation in Preterms With Closed-loop Oxygen Control","Does Closed-loop Automated Oxygen Control Reduce the Duration of Mechanical Ventilation? A Randomised Controlled Trial in Ventilated Preterm Infants","Inclusion Criteria:\n\n* Preterm infants less than 31 weeks completed gestation at birth requiring mechanical ventilation and admitted to King's NICU in the first 48 hours after birth\n\nExclusion Criteria:\n\n* Preterm infants above 31 weeks completed gestation or term born infants\n* Infants with major congenital abnormalities",{"count":587,"type":22},70,[25],"Many premature infants require respiratory support in the newborn period. Mechanical ventilation although life-saving is linked to complications for the lungs and other organs and its duration should be kept to a minimum. The use of supplemental oxygen may also increase the risk of comorbidities such as retinopathy of prematurity. Therefore, oxygen saturation levels and the amount of inspired oxygen concentration provided should be continuously monitored.\n\nOxygen control can be performed manually or with the use of a computer software incorporated into the ventilator that is called 'closed loop automated oxygen control'(CLAC). The software uses an algorithm that automatically adjusts the amount of inspired oxygen to maintain oxygen saturation levels in a target range. Evidence suggests that CLAC increases the time spent in the desired oxygen target range but there are no data to determine the effect on important clinical outcomes. A previous study has also demonstrated that CLAC reduces the inspired oxygen concentration more rapidly when compared to manual control. That could help infants come off the ventilator sooner.\n\nWith this study we want to compare the time preterm infants spend on the ventilator when we use the software to automatically monitor their oxygen levels with those infants whose oxygen is adjusted manually by the clinical team. That could help us understand if the use of automated oxygen control reduces the duration of mechanical ventilation and subsequently the complications related to it.",[591,62,592],"Infant, Premature, Diseases","Mechanical Ventilation Complication",{"date":573,"type":37},{"date":595,"type":37},"2021-09-05",{"date":597,"type":22},"2025-03",{"name":43,"class":44},{"id":600,"slug":601,"hasResults":12,"nctId":602,"briefTitle":603,"officialTitle":603,"acronym":604,"eligibilityCriteria":605,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":606,"enrollmentInfo":607,"targetDuration":4,"studyType":23,"phases":608,"briefSummary":609,"conditions":610,"keywords":612,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":614,"lastUpdatePostDateStruct":615,"startDateStruct":617,"completionDateStruct":619,"leadSponsor":621,"locationsCount":4},"100552164","phase-3-escalation-of-medical-therapy-following-multimodality-plaque-evaluation-in-high-risk-chronic-coronary-syndromes-100552164","NCT06469528","ESCALATion of Medical Therapy Following Multimodality Plaque Evaluation in High-risk Chronic Coronary Syndromes","ESCALATE","Inclusion Criteria:\n\n1. Ability to provide written informed consent\n2. Age 18 to 90 years old\n3. Male, or female of non-child-bearing potential\n4. Elevated clinical risk, as evidenced by ≥1 of:\n\n   * Previous spontaneous acute myocardial infarction (diagnosed according to the universal MI criteria) with or without persistent ST-segment elevation\n   * Previous stroke or intervention for peripheral arterial disease (i.e., evidence of atherosclerotic disease affecting \\>1 vascular bed)\n   * Established diagnosis of diabetes mellitus\n   * Systemic Coronary Risk Estimation 2 (SCORE2) or Systemic Coronary Risk Estimation 2 - Older Persons (SCORE2-OP) algorithm 10-year risk of fatal and non-fatal myocardial infarction or stroke \\>10%\n5. Documented evidence of coronary artery disease, with an angiographically moderate stenosis on invasive coronary angiography (30-80%)\n\n   \\- At least one non-flow limiting (FFR \\>0.80) moderate lesion with TCFA (minimum fibrous cap thickness of less than or equal to120µm and lipid arc \\>90°)\n6. History of prescribed statin therapy, at a stable dose, for \\>4 weeks\n7. Evidence of residual inflammation at baseline (i.e., high-sensitivity CRP ≥2)\n\nExclusion Criteria:\n\n1. Women who are pregnant, breast feeding, or of child-bearing potential\n2. Symptoms of unstable angina, characterised as: angina at rest; new onset of severe exertional angina (CCS grade III or higher for \\\u003C4 weeks); or distinct, sudden, intensification of previously stable angina\n3. Previous spontaneous acute myocardial infarction (diagnosed according to the universal MI criteria) with or without persistent ST-segment elevation \\\u003C4 weeks from recruitment\n4. Previous coronary artery bypass grafting\n5. Known chronic total occlusion of coronary artery\n6. Chronic kidney disease with eGFR \\\u003C50 mL\u002Fmin\u002F1.73 m2 per MDRD formula or renal replacement therapy at baseline assessment\n7. Known active or recurrent hepatic disorder (including cirrhosis, hepatitis B and hepatitis C, or confirmed ALT\u002FAST levels \\> 3 times ULN or total bilirubin \\> 2 times ULN) at baseline assessment\n8. Symptoms of severe heart failure (systolic or diastolic) with New York Heart Association (NYHA) Functional Classification 3 or 4\n9. Moderate or severe valvular heart disease considered likely to require intervention\n10. History of blood dyscrasia including anaemia, thrombocytopenia, neutrophilia, leukopenia or other abnormality of blood count at baseline\n11. Peripheral neuritis, myositis or marked myo-sensitivity to statins\n12. A history of alcohol and\u002For substance abuse that could interfere with the conduct of the trial\n13. Patients with suspected or proven immunocompromised state, including:\n\n    1. those with evidence of Human Immunodeficiency Virus (HIV) infection; Patients on anti-retroviral therapy are excluded\n    2. those with any other medical condition which in the opinion of the investigator places the patient at unacceptable risk for participation in immunomodulatory therapy\n14. History of hypersensitivity to the study drug or its constituents\n15. Patients who have received an investigational drug or device within 30 days (inclusive) of baseline assessment, or who are expected to participate in any other investigational drug or device study during the conduct of this trial\n16. Any biologic drugs targeting the immune system (for example, TNF blockers, anakinra, rituximab, abatacept, tocilizumab)\n17. Established long-term pharmacotherapy with a strong CYP3A4 inhibitor or a P-glycoprotein inhibitor (P-gpi) (e.g., macrolide antibiotics, ciclosporin, ketoconazole, itraconazole, voriconazole, HIV protease inhibitors, verapamil, diltiazem and disulfiram)\n18. Contraindications to intravenous adenosine will exclude patients from adenosine induced hyperaemia\n19. Any life-threatening condition with life expectancy \\\u003C6 months that might prevent the patient from completing the study.","90 Years",{"count":376,"type":22},[110],"ESCALATE will provide a thorough investigation of how anti-inflammatory therapy, with low-dose colchicine, affects patients with stable coronary artery disease. Using traditional clinical risk factors and multimodality intracoronary imaging, the investigators will identify patients with the greatest clinical risk.\n\nParticipants will undergo repeat multimodality intracoronary imaging assessment at 6 months to measure the impact once-daily low-dose colchicine therapy on the structure and function of coronary arteries.\n\nThis study will provide valuable insights into how anti-inflammatory therapies, such as colchicine, may improve outcomes in patients with coronary artery disease.",[611],"Coronary Artery Disease",[613],"Chronic coronary syndromes","2024-06-17",{"date":616,"type":37},"2024-06-21",{"date":618,"type":22},"2024-06-24",{"date":620,"type":22},"2026-10-05",{"name":43,"class":44},""]